1 To further understand what factors might influence whether patients were likely to maintain, regain, or lose more weight, we studied 25,552 patients prescribed semaglutide and 33,456 patients prescribed liraglutide for at least 90 days continuously between January 1, 2017, and February 1, 2023
Tirzepatide (weekly injection) is a dual GIP/GLP-1 agonist that may produce even greater results
Circulation 2024;150:1781-90.ArticlePubMed 120
Jan 18 2022;20(1):16
Other reported effects include fatigue, headache, and occasional dizziness
In contrast, ferroptosis inhibition via iron chelation or lipid radical scavenges blocked this Hmox1 activation-induced cardiac damage, supporting a ferroptosis targeting therapeutic strategy to alleviate cardiomyopathy in SCD 46